Immunogenicity Studies of Plant-Produced SARS-CoV-2 Receptor Binding Domain-Based Subunit Vaccine Candidate with Different Adjuvant Formulations
Due to the rapid transmission of the coronavirus disease 2019 (COVID-19) causing serious public health problems and economic burden, the development of effective vaccines is a high priority for controlling the virus spread. Our group has previously demonstrated that the plant-produced receptor-bindi...
Main Authors: | , , , , , , , , , , |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2021-07-01
|
Series: | Vaccines |
Subjects: | |
Online Access: | https://www.mdpi.com/2076-393X/9/7/744 |
id |
doaj-2792060f52cd415da0fa8d5e86b75c31 |
---|---|
record_format |
Article |
spelling |
doaj-2792060f52cd415da0fa8d5e86b75c312021-07-23T14:10:40ZengMDPI AGVaccines2076-393X2021-07-01974474410.3390/vaccines9070744Immunogenicity Studies of Plant-Produced SARS-CoV-2 Receptor Binding Domain-Based Subunit Vaccine Candidate with Different Adjuvant FormulationsKonlavat Siriwattananon0Suwimon Manopwisedjaroen1Balamurugan Shanmugaraj2Eakachai Prompetchara3Chutitorn Ketloy4Supranee Buranapraditkun5Kittipan Tharakhet6Papatsara Kaewpang7Kiat Ruxrungtham8Arunee Thitithanyanont9Waranyoo Phoolcharoen10Research Unit for Plant-Produced Pharmaceuticals, Chulalongkorn University, Bangkok 10330, ThailandDepartment of Microbiology, Faculty of Science, Mahidol University, Bangkok 10400, ThailandBaiya Phytopharm Co., Ltd., Bangkok 10330, ThailandCenter of Excellence in Vaccine Research and Development (Chula Vaccine Research Center, Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok 10330, ThailandCenter of Excellence in Vaccine Research and Development (Chula Vaccine Research Center, Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok 10330, ThailandCenter of Excellence in Vaccine Research and Development (Chula Vaccine Research Center, Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok 10330, ThailandCenter of Excellence in Vaccine Research and Development (Chula Vaccine Research Center, Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok 10330, ThailandCenter of Excellence in Vaccine Research and Development (Chula Vaccine Research Center, Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok 10330, ThailandCenter of Excellence in Vaccine Research and Development (Chula Vaccine Research Center, Chula VRC), Faculty of Medicine, Chulalongkorn University, Bangkok 10330, ThailandDepartment of Microbiology, Faculty of Science, Mahidol University, Bangkok 10400, ThailandResearch Unit for Plant-Produced Pharmaceuticals, Chulalongkorn University, Bangkok 10330, ThailandDue to the rapid transmission of the coronavirus disease 2019 (COVID-19) causing serious public health problems and economic burden, the development of effective vaccines is a high priority for controlling the virus spread. Our group has previously demonstrated that the plant-produced receptor-binding domain (RBD) of SARS-CoV-2 fused with Fc of human IgG was capable of eliciting potent neutralizing antibody and cellular immune responses in animal studies, and the immunogenicity could be improved by the addition of an alum adjuvant. Here, we performed a head-to-head comparison of different commercially available adjuvants, including aluminum hydroxide gel (alum), AddaVax (MF59), monophosphoryl lipid A from <i>Salmonella minnesota</i> R595 (mPLA-SM), and polyinosinic-polycytidylic acid (poly(I:C)), in mice by combining them with plant-produced RBD-Fc, and the differences in the immunogenicity of RBD-Fc with different adjuvants were evaluated. The specific antibody responses in terms of total IgG, IgG1, and IgG2a subtypes and neutralizing antibodies, as well as vaccine-specific T-lymphocyte responses, induced by the different tested adjuvants were compared. We observed that all adjuvants tested here induced a high level of total IgG and neutralizing antibodies, but mPLA-SM and poly (I:C) showed the induction of a balanced IgG1 and IgG2a (Th2/Th1) immune response. Further, poly (I:C) significantly increased the frequency of IFN-γ-expressing cells compared with control, whereas no significant difference was observed between the adjuvanted groups. This data revealed the adjuvants’ role in enhancing the immune response of RBD-Fc vaccination and the immune profiles elicited by different adjuvants, which could prove helpful for the rational development of next-generation SARS-CoV-2 RBD-Fc subunit vaccines. However, additional research is essential to further investigate the efficacy and safety of this vaccine formulation before clinical trials.https://www.mdpi.com/2076-393X/9/7/744adjuvantCOVID-19SARS-CoV-2receptor-binding domainplant-based vaccinesubunit vaccine |
collection |
DOAJ |
language |
English |
format |
Article |
sources |
DOAJ |
author |
Konlavat Siriwattananon Suwimon Manopwisedjaroen Balamurugan Shanmugaraj Eakachai Prompetchara Chutitorn Ketloy Supranee Buranapraditkun Kittipan Tharakhet Papatsara Kaewpang Kiat Ruxrungtham Arunee Thitithanyanont Waranyoo Phoolcharoen |
spellingShingle |
Konlavat Siriwattananon Suwimon Manopwisedjaroen Balamurugan Shanmugaraj Eakachai Prompetchara Chutitorn Ketloy Supranee Buranapraditkun Kittipan Tharakhet Papatsara Kaewpang Kiat Ruxrungtham Arunee Thitithanyanont Waranyoo Phoolcharoen Immunogenicity Studies of Plant-Produced SARS-CoV-2 Receptor Binding Domain-Based Subunit Vaccine Candidate with Different Adjuvant Formulations Vaccines adjuvant COVID-19 SARS-CoV-2 receptor-binding domain plant-based vaccine subunit vaccine |
author_facet |
Konlavat Siriwattananon Suwimon Manopwisedjaroen Balamurugan Shanmugaraj Eakachai Prompetchara Chutitorn Ketloy Supranee Buranapraditkun Kittipan Tharakhet Papatsara Kaewpang Kiat Ruxrungtham Arunee Thitithanyanont Waranyoo Phoolcharoen |
author_sort |
Konlavat Siriwattananon |
title |
Immunogenicity Studies of Plant-Produced SARS-CoV-2 Receptor Binding Domain-Based Subunit Vaccine Candidate with Different Adjuvant Formulations |
title_short |
Immunogenicity Studies of Plant-Produced SARS-CoV-2 Receptor Binding Domain-Based Subunit Vaccine Candidate with Different Adjuvant Formulations |
title_full |
Immunogenicity Studies of Plant-Produced SARS-CoV-2 Receptor Binding Domain-Based Subunit Vaccine Candidate with Different Adjuvant Formulations |
title_fullStr |
Immunogenicity Studies of Plant-Produced SARS-CoV-2 Receptor Binding Domain-Based Subunit Vaccine Candidate with Different Adjuvant Formulations |
title_full_unstemmed |
Immunogenicity Studies of Plant-Produced SARS-CoV-2 Receptor Binding Domain-Based Subunit Vaccine Candidate with Different Adjuvant Formulations |
title_sort |
immunogenicity studies of plant-produced sars-cov-2 receptor binding domain-based subunit vaccine candidate with different adjuvant formulations |
publisher |
MDPI AG |
series |
Vaccines |
issn |
2076-393X |
publishDate |
2021-07-01 |
description |
Due to the rapid transmission of the coronavirus disease 2019 (COVID-19) causing serious public health problems and economic burden, the development of effective vaccines is a high priority for controlling the virus spread. Our group has previously demonstrated that the plant-produced receptor-binding domain (RBD) of SARS-CoV-2 fused with Fc of human IgG was capable of eliciting potent neutralizing antibody and cellular immune responses in animal studies, and the immunogenicity could be improved by the addition of an alum adjuvant. Here, we performed a head-to-head comparison of different commercially available adjuvants, including aluminum hydroxide gel (alum), AddaVax (MF59), monophosphoryl lipid A from <i>Salmonella minnesota</i> R595 (mPLA-SM), and polyinosinic-polycytidylic acid (poly(I:C)), in mice by combining them with plant-produced RBD-Fc, and the differences in the immunogenicity of RBD-Fc with different adjuvants were evaluated. The specific antibody responses in terms of total IgG, IgG1, and IgG2a subtypes and neutralizing antibodies, as well as vaccine-specific T-lymphocyte responses, induced by the different tested adjuvants were compared. We observed that all adjuvants tested here induced a high level of total IgG and neutralizing antibodies, but mPLA-SM and poly (I:C) showed the induction of a balanced IgG1 and IgG2a (Th2/Th1) immune response. Further, poly (I:C) significantly increased the frequency of IFN-γ-expressing cells compared with control, whereas no significant difference was observed between the adjuvanted groups. This data revealed the adjuvants’ role in enhancing the immune response of RBD-Fc vaccination and the immune profiles elicited by different adjuvants, which could prove helpful for the rational development of next-generation SARS-CoV-2 RBD-Fc subunit vaccines. However, additional research is essential to further investigate the efficacy and safety of this vaccine formulation before clinical trials. |
topic |
adjuvant COVID-19 SARS-CoV-2 receptor-binding domain plant-based vaccine subunit vaccine |
url |
https://www.mdpi.com/2076-393X/9/7/744 |
work_keys_str_mv |
AT konlavatsiriwattananon immunogenicitystudiesofplantproducedsarscov2receptorbindingdomainbasedsubunitvaccinecandidatewithdifferentadjuvantformulations AT suwimonmanopwisedjaroen immunogenicitystudiesofplantproducedsarscov2receptorbindingdomainbasedsubunitvaccinecandidatewithdifferentadjuvantformulations AT balamuruganshanmugaraj immunogenicitystudiesofplantproducedsarscov2receptorbindingdomainbasedsubunitvaccinecandidatewithdifferentadjuvantformulations AT eakachaiprompetchara immunogenicitystudiesofplantproducedsarscov2receptorbindingdomainbasedsubunitvaccinecandidatewithdifferentadjuvantformulations AT chutitornketloy immunogenicitystudiesofplantproducedsarscov2receptorbindingdomainbasedsubunitvaccinecandidatewithdifferentadjuvantformulations AT supraneeburanapraditkun immunogenicitystudiesofplantproducedsarscov2receptorbindingdomainbasedsubunitvaccinecandidatewithdifferentadjuvantformulations AT kittipantharakhet immunogenicitystudiesofplantproducedsarscov2receptorbindingdomainbasedsubunitvaccinecandidatewithdifferentadjuvantformulations AT papatsarakaewpang immunogenicitystudiesofplantproducedsarscov2receptorbindingdomainbasedsubunitvaccinecandidatewithdifferentadjuvantformulations AT kiatruxrungtham immunogenicitystudiesofplantproducedsarscov2receptorbindingdomainbasedsubunitvaccinecandidatewithdifferentadjuvantformulations AT aruneethitithanyanont immunogenicitystudiesofplantproducedsarscov2receptorbindingdomainbasedsubunitvaccinecandidatewithdifferentadjuvantformulations AT waranyoophoolcharoen immunogenicitystudiesofplantproducedsarscov2receptorbindingdomainbasedsubunitvaccinecandidatewithdifferentadjuvantformulations |
_version_ |
1721285488377069568 |